Ponvory

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ponesimod

Available from:

Janssen-Cilag International N.V.   

ATC code:

L04AA

INN (International Name):

ponesimod

Therapeutic group:

Imunosupresivi

Therapeutic area:

Multiplo Sklerozo, Recidivno-Nakazila

Therapeutic indications:

Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Product summary:

Revision: 3

Authorization status:

Pooblaščeni

Authorization date:

2021-05-19

Patient Information leaflet

                                38
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Ponvory 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
39
PODATKI NA PRIMARNI OVOJNINI
ZUNANJA ZGIBANKA ZAČETNEGA PAKIRANJA
1.
IME ZDRAVILA
Ponvory 2 mg filmsko obložene tablete
Ponvory 3 mg filmsko obložene tablete
Ponvory 4 mg filmsko obložene tablete
Ponvory 5 mg filmsko obložene tablete
Ponvory 6 mg filmsko obložene tablete
Ponvory 7 mg filmsko obložene tablete
Ponvory 8 mg filmsko obložene tablete
Ponvory 9 mg filmsko obložene tablete
Ponvory 10 mg filmsko obložene tablete
ponesimod
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo. Za dodatne informacije glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
Začetno pakiranje
Eno pakiranje s 14 filmsko obloženimi tabletami za 2-tedenski
razpored zdravljenja vsebuje:
2 filmsko obloženi tableti zdravila Ponvory 2 mg
2 filmsko obloženi tableti zdravila Ponvory 3 mg
2 filmsko obloženi tableti zdravila Ponvory 4 mg
1 filmsko obloženo tableto zdravila Ponvory 5 mg
1 filmsko obloženo tableto zdravila Ponvory 6 mg
1 filmsko obloženo tableto zdravila Ponvory 7 mg
1 filmsko obloženo tableto zdravila Ponvory 8 mg
1 filmsko obloženo tableto zdravila Ponvory 9 mg
3 filmsko obložene tablete zdravila Ponvory 10 mg
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
peroralna uporaba
Pred uporabo preberite priloženo navodilo!
(1) Pritisnite in držite.
40
(2) Izvlecite.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o
katerem koli domnevnem
neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o
neželenih učinkih.
1.
IME ZDRAVILA
Ponvory 2 mg filmsko obložene tablete
Ponvory 3 mg filmsko obložene tablete
Ponvory 4 mg filmsko obložene tablete
Ponvory 5 mg filmsko obložene tablete
Ponvory 6 mg filmsko obložene tablete
Ponvory 7 mg filmsko obložene tablete
Ponvory 8 mg filmsko obložene tablete
Ponvory 9 mg filmsko obložene tablete
Ponvory 10 mg filmsko obložene tablete
Ponvory 20 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ponvory 2 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 2 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 23 mg laktoze.
Ponvory 3 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 3 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 22 mg laktoze.
Ponvory 4 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 4 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 21 mg laktoze.
Ponvory 5 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 5 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 118 mg laktoze.
Ponvory 6 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 6 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 117 mg laktoze.
3
Ponvory 7 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 7 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 117 mg laktoze.
Ponvory 8 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 8 mg ponesimoda.
_Pomožna snov z znanim učinkom_
Ena tableta vsebuje 116 mg laktoze.
Ponvory 9 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 9 mg ponesimoda.
_Pomožna snov z znanim učinkom
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-03-2024
Public Assessment Report Public Assessment Report Bulgarian 21-09-2023
Patient Information leaflet Patient Information leaflet Spanish 20-03-2024
Public Assessment Report Public Assessment Report Spanish 21-09-2023
Patient Information leaflet Patient Information leaflet Czech 20-03-2024
Public Assessment Report Public Assessment Report Czech 21-09-2023
Patient Information leaflet Patient Information leaflet Danish 20-03-2024
Public Assessment Report Public Assessment Report Danish 21-09-2023
Patient Information leaflet Patient Information leaflet German 20-03-2024
Public Assessment Report Public Assessment Report German 21-09-2023
Patient Information leaflet Patient Information leaflet Estonian 20-03-2024
Public Assessment Report Public Assessment Report Estonian 21-09-2023
Patient Information leaflet Patient Information leaflet Greek 20-03-2024
Public Assessment Report Public Assessment Report Greek 21-09-2023
Patient Information leaflet Patient Information leaflet English 20-03-2024
Public Assessment Report Public Assessment Report English 21-09-2023
Patient Information leaflet Patient Information leaflet French 20-03-2024
Public Assessment Report Public Assessment Report French 21-09-2023
Patient Information leaflet Patient Information leaflet Italian 20-03-2024
Public Assessment Report Public Assessment Report Italian 21-09-2023
Patient Information leaflet Patient Information leaflet Latvian 20-03-2024
Public Assessment Report Public Assessment Report Latvian 21-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-03-2024
Public Assessment Report Public Assessment Report Lithuanian 21-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 20-03-2024
Public Assessment Report Public Assessment Report Hungarian 21-09-2023
Patient Information leaflet Patient Information leaflet Maltese 20-03-2024
Public Assessment Report Public Assessment Report Maltese 21-09-2023
Patient Information leaflet Patient Information leaflet Dutch 20-03-2024
Public Assessment Report Public Assessment Report Dutch 21-09-2023
Patient Information leaflet Patient Information leaflet Polish 20-03-2024
Public Assessment Report Public Assessment Report Polish 21-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 20-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 20-03-2024
Public Assessment Report Public Assessment Report Portuguese 21-09-2023
Patient Information leaflet Patient Information leaflet Romanian 20-03-2024
Public Assessment Report Public Assessment Report Romanian 21-09-2023
Patient Information leaflet Patient Information leaflet Slovak 20-03-2024
Public Assessment Report Public Assessment Report Slovak 21-09-2023
Patient Information leaflet Patient Information leaflet Finnish 20-03-2024
Public Assessment Report Public Assessment Report Finnish 21-09-2023
Patient Information leaflet Patient Information leaflet Swedish 20-03-2024
Public Assessment Report Public Assessment Report Swedish 21-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 20-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 20-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 20-03-2024
Patient Information leaflet Patient Information leaflet Croatian 20-03-2024
Public Assessment Report Public Assessment Report Croatian 21-09-2023

Search alerts related to this product

View documents history